186 related articles for article (PubMed ID: 16286751)
1. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
Trefzer U; Sterry W
Dermatology; 2005; 211(4):370-1. PubMed ID: 16286751
[No Abstract] [Full Text] [Related]
2. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Damian DL; Shannon KF; Saw RP; Thompson JF
Australas J Dermatol; 2009 Nov; 50(4):266-71. PubMed ID: 19916970
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
4. Topical imiquimod in the treatment of metastatic melanoma to skin.
Wolf IH; Smolle J; Binder B; Cerroni L; Richtig E; Kerl H
Arch Dermatol; 2003 Mar; 139(3):273-6. PubMed ID: 12622616
[No Abstract] [Full Text] [Related]
5. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
Damian DL; Thompson JF
J Am Acad Dermatol; 2007 May; 56(5):869-71. PubMed ID: 17276544
[TBL] [Abstract][Full Text] [Related]
6. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
7. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone.
Hinz T; Ehler LK; Bieber T; Schmid-Wendtner MH
Eur J Dermatol; 2013; 23(4):532-3. PubMed ID: 24002471
[No Abstract] [Full Text] [Related]
8. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
9. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of metastatic malignant melanoma localized to an extremity].
Jacobsen KD; Tausjø J; Hager B; Gundersen S
Tidsskr Nor Laegeforen; 2010 Jan; 130(1):21-4. PubMed ID: 20094118
[TBL] [Abstract][Full Text] [Related]
11. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
12. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
13. Dramatic regression of cutaneous, nodal, and visceral melanoma metastases.
Damian DL; Saw RPM
J Am Acad Dermatol; 2011 Sep; 65(3):665-666. PubMed ID: 21839330
[No Abstract] [Full Text] [Related]
14. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
15. [Marked regression of melanoma metastases under combined chemotherapy].
Klemm-Mayer H; Rasokat H; Wagner G
Z Hautkr; 1984 Apr; 59(7):443-5. PubMed ID: 6730608
[TBL] [Abstract][Full Text] [Related]
16. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
17. [Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)].
Trcka J; Kämpgen E; Becker JC; Schwaaf A; Bröcker EB
Hautarzt; 1998 Jan; 49(1):17-22. PubMed ID: 9522188
[TBL] [Abstract][Full Text] [Related]
18. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
19. [Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil].
Florin V; Vercambre-Darras S; Piette F; Mortier L
Ann Dermatol Venereol; 2008; 135(8-9):603-4. PubMed ID: 18789300
[No Abstract] [Full Text] [Related]
20. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
[Next] [New Search]
